EORTC/LinkedIn
Jul 10, 2025, 20:44
We’re Excited to Announce That the First Patient Has Been Randomised in the PROLoNG Study – EORTC
EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:
“We’re excited to announce that the first patient has been randomised in the PROLoNG study!
The patient was enrolled at Hospital Universitari Vall d’Hebron, under the supervision of Principal Investigator Irene Braña.
The EORTC-2014 PROLoNg study focuses on Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomised phase III study.
Two Spanish sites are currently active in this international trial, with more to follow soon.
Learn more.
The PROLoNg study is supported by MSD,
Spanish Association Against Cancer, EORTC Cancer Research Fund, and Belgian Foundation Against Cancer.”
More posts featuring EORTC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 21, 2025, 23:33
Aug 21, 2025, 20:00
Aug 21, 2025, 15:59